-
21
The Measurement of Strength in Children: Is the Peak Value Truly Maximal?
Published 2020-12-01Get full text
Article -
22
Posterior Auricle Bilobed Cartilage-skin Flap for Reconstructing the Earlobe: A Case Report
Published 2024-03-01Get full text
Article -
23
-
24
-
25
Utterances as Signals for Sharing Tacit Images in Collective Interaction
Published 2022-06-01Get full text
Article -
26
-
27
-
28
-
29
-
30
-
31
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
Published 2024-04-01Get full text
Article -
32
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
Published 2024-12-01Get full text
Article -
33
Geometric Wire-frame Fixation of Skin Grafting for Lip Reconstruction
Published 2023-09-01Get full text
Article -
34
Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
Published 2024-12-01Get full text
Article -
35
Cheek Reconstruction with a Nasolabial External-Rotation Flap
Published 2024-01-01Get full text
Article -
36
Quercetin inhibits adipogenesis of muscle progenitor cells in vitro
Published 2018-03-01Get full text
Article -
37
-
38
Fatigue‐resistant Fe‐Mn‐Si‐based alloy seismic dampers to counteract long‐period ground motion
Published 2021-01-01Get full text
Article -
39
-
40
Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Published 2023-11-01“…Teppei Hagino,1 Risa Hamada,2 Mai Yoshida,2 Eita Fujimoto,3 Hidehisa Saeki,2 Naoko Kanda1 1Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan; 2Department of Dermatology, Nippon Medical School, Tokyo, Japan; 3Fujimoto Dermatology Clinic, Funabashi, JapanCorrespondence: Teppei Hagino, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan, Tel +81 476 99 1111, Fax +81 476 99 1911, Email teppei-hagino@nms.ac.jpPurpose: To investigate the therapeutic effectiveness and safety of Janus kinase 1 inhibitor upadacitinib in adolescent patients with atopic dermatitis (AD).Patients and Methods: This study examined therapeutic effectiveness and safety of upadacitinib for 39 Japanese adolescent patients (aged 12– 17 years) diagnosed with moderate-to-severe AD from August 2021 to January 2023. …”
Get full text
Article